Nordhealth Achieves EBITDA - CAPEX Breakeven Ahead of Schedule

Helsinki, Finland - July 18, 2024 - Nordhealth is pleased to announce that it has achieved EBITDA-CAPEX breakeven in Q2 2024, excluding one-off, non-recurring items. This milestone, initially projected for Q1 2025 as outlined in the Q4 2023 Investor Presentation on March 5, 2024, and reaffirmed in the 2023 Annual Report on April 12, 2024, has been reached ahead of schedule.

Preliminary figures indicate that Nordhealth's EBITDA-CAPEX, excluding one-off, non-recurring items, will be slightly positive in Q2 2024. However, as planned, the company does not expect to maintain EBITDA-CAPEX breakeven in H2 2024 and the full year of 2024.

This accelerated improvement is primarily driven by higher-than-forecasted implementation and recurring revenues in our Veterinary business unit.

Nordhealth continues to anticipate 15-20% growth in recurring revenue in 2024 compared to 2023, calculated at a constant currency rate as of December 31, 2023. Further information on profitability guidance will be provided in our Q2 2024 Investor Presentation on August 20, 2024.

For further information, please contact:

Charles MacBain, Group CEO

charles.macbain@nordhealth.com

+44 75 3903 2200

Mari Orttenvuori, CFO

mari.orttenvuori@nordhealth.com

+358 46 8765 233

About Nordhealth

Nordhealth is a publicly listed, fast-growing cloud-based healthcare SaaS company on a mission to redefine digital healthcare. We build software that empowers veterinary and therapy professionals to provide the best possible care experiences to their patients. Our products serve more than 60,000 veterinary and therapy professionals across 13,000 in over 40 countries.

Headquartered in Helsinki, Finland, Nordhealth has a solid footprint in the Nordic region and a growing presence internationally, with over 400 employees working either remotely or from offices (collaboration hubs). Visit the company’s website at nordhealth.com.